Table 5 Univariate analysis of potential prognostic factors associated with hepatitis in DLBCL patients with resolved hepatitis B

Total

43

12

HBeAb

0.639

 –

38 (88.4)

10 (83.3)

 +

5 (11.6)

2 (16.7)

Age (years)

0.831

 ≤60

23 (53.5)

6 (50.0)

 >60

20 (46.5)

6 (50.0)

Sex

0.340

 Female

21 (48.8)

4 (33.3)

 Male

22 (51.2)

8(66.7)

ECOG PS

0.974

 0–1

36 (83.7)

10 (83.3)

 ≥2

7 (16.3)

2 (16.7)

B symptoms

0.763

 −

34 (79.1)

9 (75.0)

 +

9 (20.9)

3 (25.0)

Ann Arbor stage

0.168

 I–II

24 (55.8)

4 (33.3)

 III-IV

19 (44.2)

8 (66.7)

Liver involvement

0.447

 −

41 (95.3)

12 (100)

 +

2 (4.7)

0 (0)

Spleen involvement

0.873

 −

40 (93.0)

11 (91.7)

 +

3 (7.0)

1 (8.3)

Involved extranodal sites

0.275

 <2

35 (81.4)

8 (66.7)

 ≥2

8 (18.6)

4 (33.3)

Bone marrow involvement

0.594

 −

42 (97.7)

12 (100.0)

 +

1 (2.3)

0 (0.0)

IPI score

0.288

 0–1

18 (41.9)

3 (25.0)

 2–5

25 (58.1)

9 (75.0)

ALT

0.037

 ≤40 U/L

39 (90.7)

8 (66.7)

 >40 U/L

4 (9.3)

4 (33.3)

AST

0.005

 ≤45 U/L

41 (95.3)

8 (66.7)

 >45 U/L

2 (4.7)

4 (33.3)

TB

0.918

 ≤20.5 μmol/L

39 (90.7)

11 (91.7)

 >20.5 μmol/L

4 (9.3)

1 (8.3)

LDH

0.894

 ≤245 U/mL

26 (60.5)

7 (58.3)

 >245 U/mL

17 (39.5)

5 (41.7)